MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Deep behavioural analysis of zebrafish models of Parkinson’s disease

TM. Tzotzolaki, J. Garcia Fernandez, F. de Santis, J. Terriente (Barcelona, Spain)

Meeting: 2022 International Congress

Abstract Number: 1553

Keywords: Hypokinesia

Category: Parkinson's Disease: Pathophysiology

Objective: The objective is to characterise parkinsonian phenotypes in genetic and pharmacological models of Parkinson’s disease (PD) using zebrafish.

Background: Parkinson’s disease (PD) is a progressive nervous system disorder that affects key functions in 1% of the population aged above 60 years old. The neuropathological alterations that underlie PD include the loss of dopaminergic neurons and abnormal intraneuronal accumulation of Lewy bodies. While the pathogenesis of PD remains unclear, there is evidence that various processes might contribute to it. Currently, there is no cure available for PD patients, other than drugs to alleviate symptoms.
Here, the zebrafish is used to generate models of PD and to analyse the behavioural defects associated with disease. The small size and transparent nature of zebrafish renders it an excellent model for non-invasive circuit analysis, enabling detailed study and link of neuronal circuits with behaviour. Zebrafish are amenable to a wide range of genetic tools allowing for studies that link physiology to genetic perturbations. Furthermore, starting at larval stages, zebrafish exhibit a large collection of behaviours which can be quantified in a high-throughput manner and serve as a powerful screening tool.

Method: The pharmacological model used is based on the incubation with the neurotoxicant chemical MPTP, which is widely known chemical to kill dopaminergic cells in zebrafish and cause hypolocomotion. Additionally, several genetic models of PD have been generated using CRISPR/Cas9 to target genes associated with the disease, such as park2, park7, lrrk2 and pink1. A transgenic line overexpressing the human α-synuclein gene has also been generated.
Using these distinct PD models, a deep characterisation of locomotor patterns is conducted using a high-throughput behavioural assay to record swimming events of individual fish at a high frequency over large timescale. Kinematic parameters are analysed in three manoeuvres: fast acoustovestibular escape responses, slow forward swims and routine turns.

Results: In response to an acoustovestibular stimulus, PD mutants demonstrate long-latency escape responses, which could be regarded as a delayed response [figure1]. Additionally, PD mutants exhibit less swimming higher tail beat amplitude compared to control.

Conclusion: Altogether, by building a phenotypic profile of PD could enable screening of candidate chemicals for PD in zebrafish.

figure 1

To cite this abstract in AMA style:

TM. Tzotzolaki, J. Garcia Fernandez, F. de Santis, J. Terriente. Deep behavioural analysis of zebrafish models of Parkinson’s disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/deep-behavioural-analysis-of-zebrafish-models-of-parkinsons-disease/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/deep-behavioural-analysis-of-zebrafish-models-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley